← Back to Screener
Kyntra Bio, Inc. Common Stock (KYNB)
Price$7.34
Favorite Metrics
Price vs S&P 500 (26W)-39.98%
Price vs S&P 500 (4W)-4.17%
Market Capitalization$29.62M
P/E Ratio (Annual)0.16x
All Metrics
Revenue Growth (3Y)-64.23%
Cash Flow / Share (Quarterly)$-1.19
Price vs S&P 500 (YTD)-20.33%
Gross Margin (TTM)91.35%
Net Profit Margin (TTM)2848.63%
EPS (TTM)$45.37
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$45.37
Revenue Growth (5Y)-48.41%
EPS (Annual)$45.38
ROI (Annual)-127.92%
Gross Margin (Annual)91.37%
Net Profit Margin (5Y Avg)432.73%
Cash / Share (Quarterly)$21.99
P/E Basic Excl Extra (TTM)0.16x
Revenue Growth QoQ (YoY)-59.27%
P/E Normalized (Annual)0.16x
ROA (Last FY)153.40%
Revenue Growth TTM (YoY)-95.87%
EBITD / Share (TTM)$-12.80
ROE (5Y Avg)-47.66%
Operating Margin (TTM)-814.88%
Cash Flow / Share (Annual)$-1.19
P/B Ratio1.13x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)0.20x
Net Interest Coverage (TTM)-9.02x
ROA (TTM)122.33%
EPS Incl Extra (Annual)$45.38
Current Ratio (Annual)3.39x
Quick Ratio (Quarterly)3.23x
3-Month Avg Trading Volume0.03M
52-Week Price Return2.51%
P/E Incl Extra (TTM)0.16x
Revenue / Employee (TTM)$0
P/S Ratio (Annual)4.60x
Asset Turnover (Annual)0.05x
52-Week High$12.60
Operating Margin (5Y Avg)-375.53%
EPS Excl Extra (Annual)$45.38
CapEx CAGR (5Y)-60.58%
26-Week Price Return-33.09%
Quick Ratio (Annual)3.23x
13-Week Price Return-19.07%
Total Debt / Equity (Annual)0.08x
Current Ratio (Quarterly)3.39x
Enterprise Value$1.311
Revenue / Share Growth (5Y)-4.07%
Asset Turnover (TTM)0.04x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.16x
Pretax Margin (Annual)-905.19%
Cash / Share (Annual)$21.99
3-Month Return Std Dev59.89%
Gross Margin (5Y Avg)69.60%
Net Income / Employee (TTM)$1
ROE (Last FY)-138.69%
Net Interest Coverage (Annual)-9.02x
EPS Basic Excl Extra (Annual)$45.38
P/FCF (TTM)1.93x
Receivables Turnover (TTM)18.48x
Total Debt / Equity (Quarterly)0.59x
EPS Incl Extra (TTM)$45.37
Receivables Turnover (Annual)18.48x
ROI (TTM)-256.45%
P/S Ratio (TTM)4.60x
Pretax Margin (5Y Avg)-394.97%
Revenue / Share (Annual)$1.59
Price vs S&P 500 (52W)-32.12%
P/E Ratio (TTM)0.16x
Year-to-Date Return-16.40%
5-Day Price Return-0.41%
EPS Normalized (Annual)$45.38
ROA (5Y Avg)-4.30%
Net Profit Margin (Annual)2848.63%
Month-to-Date Return8.26%
EBITD / Share (Annual)$-12.79
Operating Margin (Annual)-814.88%
LT Debt / Equity (Annual)0.08x
ROI (5Y Avg)-42.66%
P/E Excl Extra (TTM)0.16x
LT Debt / Equity (Quarterly)0.59x
EPS Basic Excl Extra (TTM)$45.37
Inventory Turnover (TTM)0.16x
Pretax Margin (TTM)-905.20%
Price vs S&P 500 (13W)-21.45%
Beta1.05x
P/FCF (Annual)0.38x
Revenue / Share (TTM)$1.59
ROE (TTM)-290.91%
52-Week Low$4.85
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KYNBKyntra Bio, Inc. Common Stock | 4.60x | -95.87% | 91.35% | — | $7.34 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Kyntra Bio Inc is a biopharmaceutical company developing novel therapies for oncology and rare diseases. Its pipeline includes Roxadustat and FG-3246, targeting indications such as lower-risk myelodysplastic syndrome-associated anemia and metastatic castration-resistant prostate cancer.